Introduction to Advanced Surgical Techniques

Managing acromegaly remains a clinical challenge for neurosurgeons, particularly when tumors invade the parasellar region. However, recent evidence suggests that MWCS resection in acromegaly can significantly improve biochemical remission rates. While transsphenoidal surgery (TSS) is the standard care, residual tumor often persists in the medial wall of the cavernous sinus (MWCS). This occurs even in tumors classified as Knosp grades 0-2. Consequently, standard TSS might lead to suboptimal results if surgeons do not resect this wall.

A prospective study published in 2026 evaluated 12 patients who underwent TSS with selective MWCS resection. The researchers observed tumor invasion of the MWCS in 91.7% of these patients. Therefore, addressing this specific anatomical structure is vital for achieving total tumor clearance. The median follow-up for this patient series was 19 months, providing a reliable window to assess endocrine outcomes.

Benefits of MWCS Resection in Acromegaly Procedures

The primary advantage of this advanced technique is the significant enhancement of endocrine remission. Specifically, 88.9% of patients who underwent primary TSS achieved biochemical remission. This rate is remarkably high compared to historical data for invasive adenomas. Furthermore, the overall disease control reached 91.7% across the entire study group. Even in re-operation cases, the technique provided a pathway to disease control that traditional methods might miss.

Safety is a critical consideration for any skull base procedure. Surgeons in this series performed the selective resection without any carotid artery injuries or permanent neurological deficits. Moreover, the study demonstrates that the technique can be safely executed by experienced teams. Consequently, this approach offers a favorable risk-benefit profile for patients with growth hormone-secreting adenomas.

Clinical Implications for Practice

Integrating MWCS resection into the surgical workflow for acromegaly may transform patient outcomes. Because the medial wall is a common site for microscopic invasion, its removal ensures a more radical resection. Additionally, this technique helps in lowering the burden of postoperative medical therapy. In conclusion, additional selective resection of the MWCS during TSS appears to be a safe and effective strategy that enhances long-term hormonal control.

Frequently Asked Questions

What is the medial wall of the cavernous sinus (MWCS)?

The MWCS is a thin dural layer that separates the pituitary fossa from the cavernous sinus. It frequently serves as a bridge for tumor cells to invade the parasellar space in acromegaly patients.

Why does MWCS resection in acromegaly improve surgical success?

Tumor cells often invade the medial wall even when imaging suggests no major invasion. Removing this wall ensures that microscopic residual disease is eliminated, which is the primary reason for improved endocrine remission.

Is the procedure safe for the internal carotid artery?

Yes, when performed by experienced pituitary surgeons using high-definition endoscopes, the procedure is safe. Current studies report zero carotid injuries or permanent neurological deficits associated with the selective resection of the medial wall.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Vergeer RA et al. Selective resection of the medial wall of the cavernous sinus in acromegaly: patient series. J Neurosurg Case Lessons. 2026 Apr 13. doi: undefined. PMID: 41974060.

Mohyeldin A, et al. Somatotroph Adenomas have a Predilection to Invade the Cavernous Sinus and Resection of the Medial Wall of the Cavernous Sinus Offers the Highest Potential for Biochemical Remission in Acromegaly. Journal of the Endocrine Society. 2021;5(Suppl 1):A555-A556.

Cohen-Cohen S, et al. Predicting biochemical remission after surgical management of GH-secreting adenomas. World Neurosurg. 2024;182:e576-e585.